Francesco Pellegrino

Dr. Francesco Pellegrino

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2023 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
FPFrancesco Pellegrino
Francesco Pellegrino
IRIrene Raffaldi
Irene Raffaldi
RRRoberta Rossi
Roberta Rossi
BVBarbara De Vito
Barbara De Vito
MPManuela Pagano
Manuela Pagano
CBClaudia Bondone
Claudia Bondone
Drowning is the third leading cause of injury death in the pediatric population worldwide, with incidence peaking among those aged 1–4 years and again in adolescence.The purpose of this commentary is to review the basic pathophysiology of drowninginjury and factors that affect the outcome, such as submersion and hypothermia. We also discuss principles of prehospital and in-hospital management, comprising resuscitation and stabilization, administration of oxygen and intravenous liquids, and central reheating.Even though the mortality rate has decreased in recent years, further investments and safety measures are needed to prevent child drowning deaths.

1 December 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
MDMarco Denina
Marco Denina
FPFrancesco Pellegrino
Francesco Pellegrino
FMFrancesco Morotti
Francesco Morotti
PCPaola Coppo
Paola Coppo
IBIlaria Maria Bonsignori
Ilaria Maria Bonsignori
FLFrancesco Licciardi
Francesco Licciardi

1 October 2021 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
FPFrancesco Pellegrino
Francesco Pellegrino
ITIrene Tardivo
Irene Tardivo

1 March 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FPFrancesco Pellegrino
Francesco Pellegrino
ETElisa Tirtei
Elisa Tirtei
FDFederico Divincenzo
Federico Divincenzo
ACAnna Campello
Anna Campello
CRCarlotta Rubino
Carlotta Rubino
FFFranca Fagioli
Franca Fagioli
Introduction: Malignant ectomesenchymoma (MEM) is a soft tissue tumour, consisting of both malignant neuroectodermal elements and one or more mesenchymal elements.Case presentation and review of the literature: Here we describe the case of a 6-months-old male, previously treated in another hospital for abdominal rhabdomyosarcoma (RMS). Histological re-examination demonstrated that the tumour had mesenchymal and neuroectodermal elements components, with a new diagnosis of abdominal-pelvic MEM. A Next-Generation Sequencing (NGS) analysis was performed on a surgical tumour specimen and revealed the presence of a somatic mutation, already reported in MEM cases. We carried out a review of the literature and we found 33 new cases of MEM since the last review. We reported the clinic-pathologic features of new cases of MEM, highlighting the role of molecular studies in supporting the diagnosis of this ambiguous tumours.Conclusion: We promote the importance of a diagnosis based on an integrative morpho-molecular approach, that routinely include molecular analysis and the use of bioinformatic mutation detection tools, to support diagnostic and therapeutical queries and to highlight tumour biology and behaviour.

3 March 2023 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
FPFrancesco Pellegrino
Francesco Pellegrino
EFElisa Funiciello
Elisa Funiciello
GPGiulia Pruccoli
Giulia Pruccoli
ESErika Silvestro
Erika Silvestro
CSCarlo Scolfaro
Carlo Scolfaro
SGSilvia Garazzino
Silvia Garazzino
Objectives: We summarized the clinical and radiological characteristics of meningitis-retention syndrome (MRS), its therapeutic options, and urological outcome, to better understand the pathogenesis of this syndrome and to evaluate the effectiveness of corticosteroids in reducing the period of urinary retention. Methods: We reported a new case of MRS in a male adolescent. We also reviewed the previously 28 reported cases of MRS, collected from inception up to September 2022. Results: MRS is characterized by aseptic meningitis and urinary retention. The mean length of the interval between the onset of the neurological signs and the urinary retention was 6.4 days. In most cases, no pathogens were isolated in cerebrospinal fluid, except for 6 cases in which Herpesviruses were detected. The urodynamic study resulted in a detrusor underactivity, with a mean period for urination recovery of 4.5 weeks, regardless of therapies. Discussion: Neurophysiological studies and electromyographic examination are not pathological, distinguishing MRS from polyneuropathies. Although there are no encephalitic symptoms or signs, and the magnetic resonance is often normal, MRS may represent a mild form of acute disseminated encephalomyelitis, without radiological detectable medullary involvement, due to the prompt use of steroids. It is believed that MRS is a self-limited disease, and no evidence suggests the effectiveness of steroids, antibiotics, and antiviral treatment in its clinical course.

27 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
FPFrancesco Pellegrino
Francesco Pellegrino
GRGiuseppe Reynolds
Giuseppe Reynolds
Simona CardaropoliSimona Cardaropoli
Simona Cardaropoli
MLMaria Luca
Maria Luca
Stefania MassurasStefania Massuras
Stefania Massuras
AMAlessandro Mussa
Alessandro Mussa
Background: PIK3CA-related overgrowth spectrum (PROS) comprises a heterogeneous group of mosaic disorders caused by activating variants in the PIK3CA gene, resulting in dysregulation of the PI3K/AKT/mTOR signaling pathway and abnormal tissue overgrowth. Targeted inhibition of this pathway has recently emerged as a promising therapeutic strategy. Methods: We conducted a literature review to identify published reports describing patients with PROS treated with alpelisib, a selective inhibitor of the p110α catalytic subunit of PI3K. Data regarding patient characteristics, genetic variants, treatment regimens, clinical outcomes, radiological response, and adverse events were extracted and analyzed. Results: Seventeen publications met the inclusion criteria, comprising a total of 114 patients treated with alpelisib. The majority of patients were pediatric (68.4%), with a median age at treatment initiation of 12 years. Clinical manifestations were heterogeneous and included segmental overgrowth, vascular malformations, and soft-tissue hypertrophy. Clinical improvement in at least one disease manifestation was reported in 111 patients (97.3%). Radiological response, defined as reduction ≥20% in lesion volume, was documented in 26 of 60 evaluable cases (47.3%). Adverse events were reported in 64 patients (56.1%) and were generally mild and manageable, with hyperglycemia and diarrhea being the most common. Conclusions: Available real-world evidence suggests that alpelisib provides meaningful clinical benefit across multiple PROS phenotypes, with an acceptable safety profile. However, current data remain limited by small cohort sizes, heterogeneous outcome reporting, and variable follow-up duration. Prospective studies with standardized outcome measures are needed to better define long-term efficacy and safety of PI3K inhibition in PROS.